Track 06 of 14
Cardio-Oncology
ICI myocarditis, CAR-T toxicity and surveillance imaging.
Cardio-oncology has become a defined subspecialty with codified ESC and ASCO management algorithms. Immune checkpoint inhibitor myocarditis remains the highest-mortality complication, with sessions covering steroid-refractory regimens (abatacept, ruxolitinib) informed by the ATRIUM trial. The track addresses CAR-T cytokine-release cardiomyopathy, anthracycline and trastuzumab surveillance with GLS and T1/T2 mapping, BTK-inhibitor AF and hypertension, radiotherapy-induced disease, and DOAC selection in cancer-associated thrombosis (Caravaggio, HOKUSAI-VTE Cancer).
Focus areas
- ICI myocarditis: ATRIUM, abatacept, ruxolitinib protocols
- CAR-T cell therapy cardiovascular toxicity
- Anthracycline and HER2 surveillance: GLS and CMR mapping
- BTK and kinase inhibitors: AF and hypertension management
- Radiation-induced coronary, valvular, and pericardial disease
- Cancer-associated thrombosis and DOAC selection
- Survivorship cardiology and primary-care interface